DAEWOONG PHARMA is a pharmaceutical company established in 2002 through the spin-off of the pharmaceutical division from DaeWoo. The company develops, manufactures, and sells prescription and over-the-counter drugs, including the novel drugs Fexuprazan (Pexulock) and Enavogliflozin (Enblo), as well as the botulinum toxin Navea (Jeuveau). Its product portfolio also includes the liver health product Ulsan, the antihypertensive Olmetec, and the gastrointestinal drug Gasmotin. DAEWOONG PHARMA operates a digital healthcare division offering the AI-based bed monitoring system thynC, the continuous glucose monitor FreeStyle Libre, the wearable ECG device Mobicare, and the ring-type blood pressure monitor CartBee. The company serves domestic and global markets, with Navea distributed internationally through partners such as Evolus. Its subsidiaries include HanAll Biopharma, which focuses on biopharmaceuticals for autoimmune and ophthalmic diseases, and PT Selatox Bio Pharma, which manages production and brand development in Indonesia.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage daewoong.co.kr
Sector Healthcare IR page daewoong.co.kr/ko
Tags
botulinum toxin, prescription drugs, digital healthcare, biopharmaceuticals, autoimmune diseases, gastroenterology, diabetes, ophthalmology, neurology, wearable devices, Fexuprazan, Pexulock, Enavogliflozin, Enblo, Navea, Jeuveau, Ulsan, Olmetec, Gasmotin, thynC, FreeStyle Libre, Mobicare, CartBee, Whisky, Bersiporocin, DWN12088, Semaglutide microneedle patch, DWP216, DWP220, HanAll Biopharma, HPI Inc., PT Selatox Bio Pharma, Biotox, Eligard, Norimix, Hairgro, Batoquelimab, HL161BKN, Imemroprubart, HL161ANS, HL192, HL036, Tafanacercept, Pangro Liquid 5%, Medisafe, Evolus, Moksha8, Oxapharma, Pharma Consulting Group S.A., Aghrass Healthcare Limited, JSC Pharmasyntez, Zydus Lifescience Global FZE, Immunovant, Harbour BioMed, NurrOn Pharmaceuticals, CSPC Pharmaceutical Group
Press page daewoong.co.kr/ko/product/news

Metrics

Valuation  
Market cap ₩ 1.436T
Market cap (USD) $ 1.057B
P/E 7.29
PEG 0.11
P/BV 1.35
P/S 0.88
P/OCF 8.86
P/FCF -13.81
Dividend yield —
Turnover / mcap —
Returns  
ROE 21.8%
ROI 19.5%
ROIC 19.6%
Profit margin 12.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 66.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.571T 1.423T 1.375T 1.28T 1.153T 1.055T 1.113T 1.031T 960.307B 883.92B 839.686B 735.889B 682.508B
Net profit 195.856B 24.735B 121.739B 42.24B 24.506B 12.753B 22.006B -1.516B 31.581B 26.97B 42.93B 31.544B 58.4B
Free cash flow -42.329B -103.653B 26.671B 53.053B 10.906B 74.495B 35.286B -9.49B 34.861B — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 176.988K 123.709K — — — — — — — — — — —
Price performance 12m 0.43 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 173B 170B 179B 206B 149B 161B 183B 180B 215B 219B
↳ YoY growth +21.7% -1.9% +5.3% +15.0% -27.6% +7.9% +13.9% -1.8% +19.6% +2.2%
↳ 5y CAGR +14.9% +14.8% +0.9% -1.5% +1.5% +0.1% +0.9% +8.1%
Borrowings, current (KRW) 108B 95.7B 207B 99.3B 147B 256B 234B 372B 0.00 162B
Borrowings, non-current (KRW) 289B — — — 91.5B 92B 115B 65B 324B 551B
Bonds payable (KRW) 99.9B 89.9B 200B 89.9B 89.9B 200B 89.8B 89.9B 194B 334B
Lease liabilities (KRW) — — 0.00 3.4B 6.56B 8B 8.2B 3.9B 3.28B 2.05B
Cash and deposits (KRW) 78.3B 91.1B 65.3B 32.1B 72.3B 75.9B 103B 112B 103B 169B
Intangible assets (KRW) 151B 174B 150B 165B 179B 225B 266B 297B 347B 368B
Right-of-use assets (KRW) — — 0.00 4.49B 7.53B 7.9B 8.18B 4.16B 19.2B 17B
Net debt (borrowings + leases - cash) (KRW) 211B 4.61B 142B 70.6B 173B 280B 254B 330B 225B 545B
Cash flow detail
Operating cash flow (KRW) 15.4B 104B 47.5B 57.6B 101B 40B 118B 136B 51.5B 149B
Purchases of property, plant and equipment (KRW) -141B -69.1B -57B -22.3B -26.5B -29.1B -65.2B -109B -155B -192B
Purchases of intangible assets (KRW) -21.8B -27.7B -72.3M -27.8B -33.2B -45.7B -48.1B -46.8B -73.9B -49.8B
Change in receivables (cash effect) (KRW) -21.2B -27.6B -12B -21.8B 53.7B -27.9B -24.4B -3.7B — —
Change in inventories (cash effect) (KRW) -23.1B -23.7B -11.3B 5.4B -9.74B -11.8B -50B -43.3B — —
Change in payables (cash effect) (KRW) 18.1B 39.1B -4.84B 11.3B 9.33B 4.92B 45.5B 32.3B — —
Dividends paid (cash effect) (KRW) -7.22B -6.19B -6.19B -6.19B -6.19B -6.46B -8.07B -7.28B -7.74B -8.08B
Interest paid (cash effect) (KRW) -7.72B -9.57B -10B -10.4B -10.7B -9.84B -11.5B -16.6B -23.1B -23.6B
Income taxes paid (cash effect) (KRW) -9.78B -7B -7.91B -22.3B -2.91B — -9.05B -8.39B -38.9B -14.5B
Share-based compensation (KRW) 194M 29.3M 633M 943M 1.19B 2B 1.84B 1.62B — —
Operating cash flow before change in receivables (KRW) 36.5B 132B 59.5B 79.4B 47.3B 67.9B 143B 140B — —
Free cash flow (OCF - PPE - intangibles) (KRW) -148B 7.18B -9.56B 7.49B 41.3B -34.8B 4.91B -20.2B -178B -92.2B
Income detail
Research and development expense (KRW) — — — — — — 164B 172B 171B 180B
Total comprehensive income (KRW) 24.6B 32.5B -14.1B 33.4B 42.5B -18.7B 52.4B 130B 20.5B 206B
Comprehensive income to owners (KRW) 25.1B 29B -15.1B 23.8B 17.4B -5.35B 47.2B 123B 33.4B 209B
Provision for credit losses (KRW) 2.02B 3.3B 3.44B 1.44B 3.6B 2.13B 2.25B 5.84B — —
Credit cost ratio (credit losses / average receivables) (%) 1.3% 1.9% 2.0% 0.8% 2.0% 1.4% 1.3% 3.2% — —
Reported Apr 1, 2019 Apr 1, 2019 May 15, 2019 Mar 30, 2020 Aug 17, 2021 Mar 20, 2024 Aug 14, 2025 Aug 14, 2025 Aug 14, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

풍문또는보도에대한해명(미확정) Bull 0 Bear 3 Other
영업(잠정)실적(공정공시) Bull 1 Bear 0 Results

Prompts

DAEWOONG PHARMA (ticker 069620), listed in South Korea.

ETFs Holding DAEWOONG PHARMA

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 574 $ 42.777K Nov 16, 2026
DEXC 0.02% 513 $ 39.522K Nov 12, 2026
DFSE 0.01% 861 $ 66.333K Nov 12, 2026
DFEM 0.01% 7,430 $ 572.419K Nov 12, 2026
DFAE 0.00% 3,471 $ 267.411K Nov 12, 2026
DFAX 0.00% 3,707 $ 285.593K Nov 12, 2026
AVEM 0.00% 2,954 $ 220.146K Nov 16, 2026
AVXC 0.00% 131 $ 9,762.72 Nov 16, 2026